221 results
Page 2 of 12
8-K
EX-10.3
eftfxv270
22 Jul 16
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
12:00am
8-K
EX-10.4
93cco9ne
22 Jul 16
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
12:00am
8-K
EX-10.1
92kqzvoxqpw ugs
22 Jul 16
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
12:00am
8-K
EX-10.2
nmcz38o011z
22 Jul 16
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
12:00am
8-K
EX-10.1
7kwhd6w8681p o0q
22 Apr 16
Termination of a Material Definitive Agreement
12:00am
DEFA14A
EX-10.1
debtwuoy88wqspc
14 Apr 16
Additional proxy soliciting materials
12:00am
DEFA14A
EX-10.3
qfzlu 0ckz1kl
14 Apr 16
Additional proxy soliciting materials
12:00am
8-K
EX-10.3
2vs2cm0o62gdhv85sgzy
14 Apr 16
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
12:00am
DEFA14A
EX-10.2
0uxql51afxnmc pnl
14 Apr 16
Additional proxy soliciting materials
12:00am
8-K
EX-10.1
x4xzf
14 Apr 16
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
12:00am
8-K
EX-10.2
1k1vu054c2thh d22m
14 Apr 16
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
12:00am
8-K
EX-10.1
vkgifm
16 Oct 15
Entry into a Material Definitive Agreement
12:00am